Genitourinary Cancers | Specialty

Dr. Jonasch on the Role of Inhibiting HIF-2α in Von Hippel-Lindau Disease–Associated RCC

August 20th 2020

Eric Jonasch, MD, discusses the role of inhibiting hypoxia-inducible factor-2α in Von Hippel-Lindau disease–associated renal cell carcinoma.

Gaining Ground With Immunotherapy in Genitourinary Malignancies

August 20th 2020

Bradley McGregor, MD, discusses some of the recent approaches that have emerged in bladder cancer and renal cell carcinoma, as well as anticipated developments in each field.

FDA Grants Durvalumab Priority Review for Fixed-Dose Use in NSCLC and Bladder Cancer

August 18th 2020

The FDA has granted a priority review designation to a supplemental biologics license application for a new 4-week, fixed-dose regimen as treatment in approved indications of non–small cell lung cancer and bladder cancer.

Dr. Sonpavde on Combining VEGF/PD-1 Inhibitors in Metastatic Urothelial Carcinoma

August 14th 2020

Guru P. Sonpavde, MD, discusses the utility of combining anti-VEGF and anti–PD-1 agents in metastatic urothelial carcinoma.

Dr. McKay on the Role of Age and Gender in Advanced RCC Outcomes

August 13th 2020

Rana R. McKay, MD, discusses the role of age and gender in advanced renal cell carcinoma outcomes. 

Combination Biomarker Is Predictive of Response to Immunotherapy in Metastatic Urothelial Carcinoma

August 13th 2020

The combination of ARID1A mutations and the immune signaling protein CXCL13 proved to be predictive of clinical response and prolonged survival after treatment with checkpoint inhibitors in patients with metastatic urothelial carcinoma.

Dr. Tykodi on the KEYNOTE-427 Trial With Pembrolizumab in RCC

August 11th 2020

Scott S. Tykodi, MD, PhD, provides background to the phase 2 KEYNOTE-427 trial with pembrolizumab in renal cell carcinoma.

Dr. Tykodi on the Clinical Implications of the KEYNOTE-427 Trial in Advanced RCC

August 10th 2020

Scott S. Tykodi, MD, PhD, discusses the clinical implications of the phase 2 KEYNOTE-427 trial in advanced renal cell carcinoma.

Dr. Choueiri on the Impact of the COVID-19 Pandemic on Treatment in RCC

August 7th 2020

Toni K. Choueiri, MD, discusses the impact the coronavirus disease 2019 pandemic has had on diagnosing and treating patients with renal cell carcinoma.

Dr. Jonasch on Next Steps With MK-6482 in Von Hippel-Lindau Disease–Associated RCC

August 6th 2020

Eric Jonasch, MD, discusses the next steps with the potent, selective, small molecule hypoxia-inducible factor-2α inhibitor MK-6482 in Von Hippel-Lindau disease–associated renal cell carcinoma.

Rapid Progress Made With Late-Line Therapies in Metastatic Urothelial Cancer

August 6th 2020

Praful K. Ravi, MD, discusses the emergence of immunotherapies, FGFR inhibitors, and antibody-drug conjugates and how they dramatically evolved the metastatic urothelial cancer treatment paradigm.

COVID-19 Spurs New Frameworks for Surgical Management of GU Cancers

August 6th 2020

Steven Lee Chang, MD, MS, discusses the impact of the COVID-19 pandemic on surgical practices, alternative options to surgery, and potential lessons to be learned from the pandemic.

Savolitinib Showcases Encouraging Efficacy in MET-Driven Papillary RCC

August 5th 2020

Savolitinib demonstrated encouraging efficacy and an improved safety profile over sunitinib in patients with MET-driven papillary renal cell carcinoma.

Dr. Choueiri on Expanding the Therapeutic Armamentarium in mRCC

August 3rd 2020

Toni K. Choueiri, MD, discusses current and emerging treatment options for patients with metastatic renal cell carcinoma.

FDA Grants Breakthrough Status to MK-6482 for Select VHL Disease–Associated RCC

July 29th 2020

The FDA has granted a breakthrough therapy designation to MK-6482 for the treatment of patients with von Hippel-Lindau disease–associated renal cell carcinoma who have nonmetastatic tumors of less than 3 centimeters, unless immediate surgery is necessitated.

Future of Treating mRCC

July 23rd 2020

Treating Patients With mRCC Beyond Second-Line

July 23rd 2020

Strategies for Switching From Frontline Therapy to Second-Line Therapy in mRCC

July 23rd 2020

Clinical Trials Shaping Treatment in Relapsed/Refractory mRCC

July 23rd 2020

Choosing Second-Line Therapy in Treatment of mRCC

July 23rd 2020